5-[3-(tert-butyl-dimethyl-silanyloxy)-4-(3-fluoro-phenyl)-butyl]-pyrrolidin-2-one | 346672-81-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[3-(tert-butyl-dimethyl-silanyloxy)-4-(3-fluoro-phenyl)-butyl]-pyrrolidin-2-one
• 英文别名: 5-[3-(Tert-butyldimethyl-silanyloxy)-4-(3-fluoro-phenyl)-butyl]-pyrrolidin-2-one；5-[3-[tert-butyl(dimethyl)silyl]oxy-4-(3-fluorophenyl)butyl]pyrrolidin-2-one
• CAS: 346672-81-9
• 化学式: C₂₀H₃₂FNO₂Si
• 分子量: 365.563
• InChiKey: NNKQTVQXEWLWJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.82
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-[3-(tert-butyl-dimethyl-silanyloxy)-4-(3-fluoro-phenyl)-butyl]-pyrrolidin-2-one 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hexamethyldisilazane 、 四丁基氟化铵 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 四氢呋喃 、 甲醇 为溶剂， 生成 4-(3-{2-[4-(3-fluoro-phenyl)-3-hydroxy-butyl]-5-oxo-pyrrolidin-1-yl}-propyl)-benzoic acid
  参考文献：
  名称：

  Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats

  摘要：

  Heptanoic acid lactams. exemplified by 2, were identified as highly selective EP4 agonists via high throughput screening. Lead optimization led to the identification of lactams with a 30-fold increase in EP4 potency in vitro. Compounds demonstrated robust bone anabolic effects when administered in vivo in rat models of osteoporosis. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.018
• 作为产物：
  描述：

  5-[4-(3-fluoro-phenyl)-3-oxo-butyl]-pyrrolidin-2-one 在 咪唑 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-[3-(tert-butyl-dimethyl-silanyloxy)-4-(3-fluoro-phenyl)-butyl]-pyrrolidin-2-one
  参考文献：
  名称：

  Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats

  摘要：

  Heptanoic acid lactams. exemplified by 2, were identified as highly selective EP4 agonists via high throughput screening. Lead optimization led to the identification of lactams with a 30-fold increase in EP4 potency in vitro. Compounds demonstrated robust bone anabolic effects when administered in vivo in rat models of osteoporosis. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.018

文献信息

• EP4 receptor selective agonists in the treatment of osteoporosis
  申请人：——

  公开号：US20010047105A1

  公开（公告）日：2001-11-29

  This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: 1 wherein the variables are as defined in the specification.

  这项发明涉及治疗低骨密度等病症的方法，特别是骨质疏松症、脆弱、骨折、骨缺陷、儿童特发性骨质流失、牙槽骨流失、下颌骨流失、骨折、骨切术、与牙周炎相关的骨流失或假体生长的方法，包括给予EP4受体选择性前列腺素激动剂。这项发明特别涉及EP4受体选择性激动剂为Formula I中的化合物的方法：1其中变量如规范中所定义。
• Methods of treatment with selective EP4 receptor agonists
  申请人：——

  公开号：US20030207925A1

  公开（公告）日：2003-11-06

  The present invention provides a method of treating hypertension, liver failure, loss of patency of ductus arteriosus, glaucoma or ocular hypertension in a patient, comprising administering to the patient a therapeutically effective amount of a selective EP 4 receptor agonist of Formula I 1 or a prodrug thereof, a pharmaceutically acceptable salt of the selective EP 4 receptor agonist or prodrug or a stereoisomer or diastereomeric mixture of the EP 4 receptor agonist, prodrug or salt, wherein the variables X, Z, Q, , and R 2 are as defined in the specification.

  本发明提供了一种治疗患有高血压、肝功能衰竭、动脉导管未开放、青光眼或眼压增高的患者的方法，包括向患者施用公式I1中的选择性EP4受体激动剂或其前药的治疗有效量、选择性EP4受体激动剂的药学上可接受的盐或前药的盐，或EP4受体激动剂、前药或盐的立体异构体或对映体混合物，其中变量X、Z、Q、和R2如规范所定义。
• Method for treating ocular hypertension
  申请人：——

  公开号：US20040254230A1

  公开（公告）日：2004-12-16

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions that are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

  本发明涉及到前列腺素E2受体EP4亚型的有效选择性激动剂，以及它们的使用或制剂在治疗青光眼和其他与患者眼内压升高有关的疾病中。本发明还涉及使用这些化合物为哺乳动物（尤其是人类）的眼提供神经保护作用。
• EP4 receptor selective agonist in the treatment of osteoporosis
  申请人：Pfizer Inc.

  公开号：US07192979B2

  公开（公告）日：2007-03-20

  This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, wherein R2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.

  本发明涉及公式I中的EP4受体选择性前列腺素激动剂，其中R2，X，Z和Q如规范中所定义。本发明还涉及含有这些化合物的制药组合物。本发明还涉及治疗低骨量症状的方法，特别是骨质疏松症，衰弱，骨质疏松性骨折，骨缺损，儿童特发性骨质流失，牙槽骨流失，下颌骨流失，骨折，骨切开术，与牙周炎相关的骨损失或哺乳动物体内的假体生长，包括给予这些化合物。
• Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats
  作者：Kimberly O. Cameron、Bruce A. Lefker、Margaret Y. Chu-Moyer、David T. Crawford、Paul DaSilva Jardine、Shari L. DeNinno、Sandra Gilbert、William A. Grasser、HuaZhu Ke、Bihong Lu、Thomas A. Owen、Vishwas M. Paralkar、Hong Qi、Dennis O. Scott、David D. Thompson、Christina M. Tjoa、Michael P. Zawistoski

  DOI：10.1016/j.bmcl.2006.01.018

  日期：2006.4

  Heptanoic acid lactams. exemplified by 2, were identified as highly selective EP4 agonists via high throughput screening. Lead optimization led to the identification of lactams with a 30-fold increase in EP4 potency in vitro. Compounds demonstrated robust bone anabolic effects when administered in vivo in rat models of osteoporosis. (C) 2006 Elsevier Ltd. All rights reserved.